Intrepid Family Office’s Iovance Biotherapeutics IOVA Stock Holding History

Intrepid Family Office’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-30,000	Closed	-$81.9K	–	44
2025 Q4	$81.9K	Sell	30,000 -10,000	-25%	-$23.1K	0.07%	36
2025 Q3	$86.8K	Buy	40,000 +15,000	+60%	+$35.4K	0.07%	36
2025 Q2	$43K	Sell	25,000 -15,000	-38%	-$37.3K	0.04%	39
2025 Q1	$133K	Buy	40,000 +10,000	+33%	+$51.6K	0.19%	29
2024 Q4	$222K	Buy	+30,000	New	+$278K	0.23%	31

Other funds holding IOVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ICM

Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return

Intrepid Family Office's IOVA Position: Q1 2026 in Review

Intrepid Family Office sold out of Iovance Biotherapeutics (IOVA) in Q1 2026, closing a stake of 30,000 shares — an estimated $81.9K sold.

Intrepid Family Office first reported a position in IOVA in Q4 2024 and held it in 5 quarters. The position peaked at $222K in Q4 2024. 286 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.

Intrepid Family Office reported no remaining Iovance Biotherapeutics position as of Q1 2026 after selling out during the quarter.
Intrepid Family Office sold 30,000 Iovance Biotherapeutics shares in Q1 2026, an estimated $81.9K.
Intrepid Family Office first reported a position in Iovance Biotherapeutics in Q4 2024 and held it in 5 quarters.
Intrepid Family Office's Iovance Biotherapeutics position peaked at $222K in Q4 2024.
286 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.

Based on Intrepid Family Office's 13F filing for Q1 2026, filed 15 May 2026.